ConductScience.org, home

Paper22992140

Immune modulation in Pompe disease treated with enzyme replacement therapy.

Banugaria SG and 2 others. Expert Rev Clin Immunol, 2012. Cited by 25 papers, by iCite.

Cite this record

ConductScience Library. Immune modulation in Pompe disease treated with enzyme replacement therapy. Papers, record 22992140. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/22992140

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Immune modulation in Pompe disease treated with enzyme replacement therapy.
PubMed
Journal
Expert Rev Clin Immunol
PubMed
Year
2012
PubMed
Publication types
Editorial
PubMed
Citations, by iCite
25
iCite
Relative citation ratio, by iCite
0.84
iCite
Revised in PubMed
2012-09-20
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Banugaria SGSuhrad G
2Patel TTTrusha T
3Kishnani PSPriya S

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Enzyme Replacement TherapyMajor topic
Glycogen Storage Disease Type IIMajor topic
ImmunomodulationMajor topic
alpha-GlucosidasesMajor topic
Animals
Antibodies
Humans
Mice

Source PubMed

Download CSV of topics

Cited by15

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 25 citations.

PMIDTitleJournalYearIn PapersSource
40123743Antibodies to recombinant human alpha-L-iduronidase prevent disease correction in cortical bone in MPS I mice.Mol Ther Methods Clin Dev2025https://conductscience.org/library/papers/40123743PubMed
39604266A novel CD71 Centyrin:Gys1 siRNA conjugate reduces glycogen synthesis and glycogen levels in a mouse model of Pompe disease.Mol Ther2025https://conductscience.org/library/papers/39604266PubMed
35248118Immune responses to alglucosidase in infantile Pompe disease: recommendations from an Italian pediatric expert panel.Ital J Pediatr2022https://conductscience.org/library/papers/35248118PubMed
29649469Phosphatidylserine Is Not Just a Cleanup Crew but Also a Well-Meaning Teacher.J Pharm Sci2018https://conductscience.org/library/papers/29649469PubMed
28874182Long-term neurologic and cardiac correction by intrathecal gene therapy in Pompe disease.Acta Neuropathol Commun2017https://conductscience.org/library/papers/28874182PubMed
28648664High dose IVIG successfully reduces high rhGAA IgG antibody titers in a CRIM-negative infantile Pompe disease patient.Mol Genet Metab2017https://conductscience.org/library/papers/28648664PubMed
27896120Non-depleting anti-CD4 monoclonal antibody induces immune tolerance to ERT in a murine model of Pompe disease.Mol Genet Metab Rep2014https://conductscience.org/library/papers/27896120PubMed
27747161Alglucosidase alfa treatment alleviates liver disease in a mouse model of glycogen storage disease type IV.Mol Genet Metab Rep2016https://conductscience.org/library/papers/27747161PubMed
27493997Durable and sustained immune tolerance to ERT in Pompe disease with entrenched immune responses.JCI Insight2016https://conductscience.org/library/papers/27493997PubMed
27488899Phosphatidylserine Converts Immunogenic Recombinant Human Acid Alpha-Glucosidase to a Tolerogenic Form in a Mouse Model of Pompe Disease.J Pharm Sci2016https://conductscience.org/library/papers/27488899PubMed
26883220The impact of the immune system on the safety and efficiency of enzyme replacement therapy in lysosomal storage disorders.J Inherit Metab Dis2016https://conductscience.org/library/papers/26883220PubMed
25881001Pharmacological Chaperone Therapy: Preclinical Development, Clinical Translation, and Prospects for the Treatment of Lysosomal Storage Disorders.Mol Ther2015https://conductscience.org/library/papers/25881001PubMed
25548186Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance.Proc Natl Acad Sci U S A2015https://conductscience.org/library/papers/25548186PubMed
24176423Clinical neurogenetics: neuropathic lysosomal storage disorders.Neurol Clin2013https://conductscience.org/library/papers/24176423PubMed
23825616Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile pompe disease: a step towards improving the efficacy of ERT.PLoS One2013https://conductscience.org/library/papers/23825616PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/22992140

GET https://conductscience.org/api/papers/v1/22992140/authors